Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Higher risk of progressing breastcancer in Kurdish population associated to CDH1 -160 C/A polymorphism 29285016 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Higher risk of progressing breastcancer in Kurdish population associated to CDH1 -160 C/A polymorphism. 1198-1205 10.17179/excli2017-843 There is an increasing interest about studying possible effects of genetic polymorphisms and risk of cancer progression. E-cadherin (CDH1) involves in many important cellular processes including (...) cell-cell interactions, cell development and genetic changes of this molecule has been associated with greater tumormetastasis. The present study was aimed to evaluate the possible role of CDH1 -160 C/A polymorphism as a potential risk factor for breastcancer in Kurdish population. This case-control study consisted of 100 breastcancer patients and 200 healthy controls. Clinicopathological findings of all individuals were reported and immunohistochemistry staining was carried out on tissue
Predictors of radiation-induced acute skin toxicity in breastcancer at a single institution: Role of fractionation and treatment volume 29556573 2018 11 14 2452-1094 3 1 2018 Jan-Mar Advances in radiation oncology Adv Radiat Oncol Predictors of radiation-induced acute skin toxicity in breastcancer at a single institution: Role of fractionation and treatment volume. 8-15 10.1016/j.adro.2017.10.007 The associations among radiation fractionation, body mass index (BMI), and acute skin toxicity (...) with adjuvant radiation for breastcancer is of increasing interest. This study evaluated the rate of grade ≥2 dermatitis and moist desquamation (MD) in patients with a high BMI who were treated to the breast or chest wall to understand the role of radiation target, fractionation regimen, and BMI. We retrospectively evaluated 280 patients treated with adjuvant radiation for breastcancer after up-front surgery. We collected information on patient demographics, disease and treatment characteristics
Abemaciclib (Verzenio) - To treat certain advanced or metastaticbreastcancers Verzenio (abemaciclib) Tablets U.S. Department of Health and Human Services Search FDA Submit search Verzenio (abemaciclib) Tablets Verzenio Company: Eli Lilly and Company Application No.: 208716 Approval Date: 09/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: October 31, 2017
Detection and analysis of circulating large intergenic nonâ€coding RNA regulator of reprogramming in plasma for breastcancer 29090518 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Detection and analysis of circulating large intergenic non-coding RNA regulator of reprogramming in plasma for breastcancer. 66-74 10.1111/1759-7714.12537 Previous studies have indicated that large intergenic non-coding RNA regulator of reprogramming (lincRNA-ROR) plays an important role (...) in regulating tumor carcinogenesis and metastasis; however, whether circulating lincRNA-ROR could function as a potential biomarker for breastcancer (BC) diagnosis and monitoring is unknown. This study was conducted to investigate circulating lincRNA-ROR in plasma as a potential biomarker for BC diagnosis and monitoring. We performed reverse transcription-quantitative-PCR to examine lincRNA-ROR expression levels in cell lines, 24 pairs of BC tissue samples, and 94 plasma samples from BC patients. Potential
Bisphosphonates and other bone agents for breastcancer. BACKGROUND: Bone is the most common site of metastatic disease associated with breastcancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breastcancer and advanced breastcancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 (...) and 2012. OBJECTIVES: To assess the effects of bisphosphonates and other bone agents in addition to anti-cancer treatment: (i) in women with early breastcancer (EBC); (ii) in women with advanced breastcancer without bone metastases (ABC); and (iii) in women with metastaticbreastcancer and bone metastases (BCBM). SEARCH METHODS: In this review update, we searched Cochrane BreastCancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials
â€œThanks for Letting Us All Share Your Mammogram Experience Virtuallyâ€: Developing a Web-Based Hub for BreastCancer Screening 29079555 2018 11 13 2369-1999 3 2 2017 Oct 27 JMIR cancer JMIR Cancer "Thanks for Letting Us All Share Your Mammogram Experience Virtually": Developing a Web-Based Hub for BreastCancer Screening. e17 10.2196/cancer.8150 The decision around whether to attend breastcancer screening can often involve making sense of confusing and contradictory information on its risks (...) and benefits. The Word of Mouth Mammogram e-Network (WoMMeN) project was established to create a Web-based resource to support decision making regarding breastcancer screening. This paper presents data from our user-centered approach in engaging stakeholders (both health professionals and service users) in the design of this Web-based resource. Our novel approach involved creating a user design group within Facebook to allow them access to ongoing discussion between researchers, radiographers
Comparison of mammography and ultrasonography findings with pathology results in patients with breastcancer in Birjand, Iran 29238489 2018 11 13 2008-5842 9 10 2017 Oct Electronic physician Electron Physician Comparison of mammography and ultrasonography findings with pathology results in patients with breastcancer in Birjand, Iran. 5494-5498 10.19082/5494 Early diagnosis of breastcancer, the incidence of which among Iranian women is about a decade earlier than in developed countries (...) , is important. To compare mammography and ultrasonography findings with those of pathology in patients with breastcancer. This descriptive cross-sectional study was performed using medical records of 79 patients with breast malignancies, who were referred to Imam Reza Hospital and private laboratories of Birjand, Iran, from December 2012 to December 2014. The patients' information was recorded using a checklist, which included name, code, age, ultrasonography, and mammography results and pathology reports
An unusual flare of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breastcancer 29308284 2018 11 13 2147-9720 4 4 2017 Dec European journal of rheumatology Eur J Rheumatol An unusual flare of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breastcancer. 278-280 10.5152/eurjrheum.2017.17036 We present the case of a patient with relapsing anti-synthetase syndrome (ASS) that may have been triggered by monoclonal antibody (...) trastuzumab therapy given for breastcancer. A 52-year-old female with a history of anti-Jo1-associated ASS went into remission with glucocorticoids and mycophenolate mofetil. Her past history included invasive ductal carcinoma of the right breast that was fully treated six years prior to the onset of ASS. She subsequently developed recurrent right-sided breastcancer that was treated with right mastectomy and six cycles of cyclophosphamide-docetaxel chemotherapy. She commenced adjuvant trastuzumab
GM-CSF promotes a supportive adipose and lung microenvironment in metastaticbreastcancer 29142902 2018 11 13 2331-4737 4 9-10 2017 Sep Oncoscience Oncoscience GM-CSF promotes a supportive adipose and lung microenvironment in metastaticbreastcancer. 126-127 10.18632/oncoscience.371 Reggiani Francesca F Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy. Bertolini Francesco F Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy. eng (...) Editorial 2017 10 23 United States Oncoscience 101636666 2331-4737 Cancer Res. 2012 Jan 1;72(1):325-34 22052460 Cancer Res. 2009 Mar 1;69(5):2133-40 19223554 BMC Cancer. 2013 Nov 09;13:535 24209831 Cancer Res. 2013 Oct 1;73(19):5880-91 23918796 Nat Cell Biol. 2017 Aug;19(8):974-987 28737771 BreastCancer Res. 2013;15(5):R102 24176089 Cancer Res. 2000 Jun 15;60(12):3239-46 10866317 Adipose tissue GM-CSF breastcancer neutrophils CONFLICTS OF INTEREST The authors declare no conflicts of interest. 2017 10
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2âˆ’ node positive breast cancerâ€”A National Cancer Database study 29067357 2018 11 13 2374-4677 3 2017 NPJ breastcancer NPJ BreastCancer Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breastcancer-A National Cancer Database study. 41 10.1038/s41523-017-0044-4 The 21-gene Recurrence Score (RS) assay is prognostic (...) and predictive of adjuvant chemotherapy benefit in node positive (N+) breastcancer (BC). We sought to evaluate use patterns of RS assay in N+, ER+/HER2- BC and the impact of RS on recommendations for adjuvant chemotherapy. Patients with T1-T4c,N1mi-N3, ER+/HER2- BC diagnosed 2010-2013 in the National Cancer Database were analyzed. Multivariable logistic regression assessed factors influencing RS testing and chemotherapy recommendations based on RS. Among 72,897 patients, RS was obtained in 20.6%, increasing
Evaluation of in vitro and in vivo anticancer potential of two 5-acetamido chalcones against breastcancer 29285012 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Evaluation of in vitro and in vivo anticancer potential of two 5-acetamido chalcones against breastcancer. 1150-1163 10.17179/excli2017-624 Two 5'acetamido chalcones, C1 and C2 were synthesized by Claisen-Schmidt condensation method and characterized by IR, LC-MS, 1 H NMR and 13 C NMR. These compounds were evaluated (...) for anticancer activity in vitro in breastcancer cell lines (MCF-7 and MDA-MB-231) using MTT assay, anti-metastatic assay, apoptotic screening by AO/EB staining and in vivo in N-Methyl-N-nitrosourea (MNU) induced breastcarcinoma model. Sprague-Dawley rats with developed tumors (50 mg/kg MNU i.p. ) were grouped in four, namely MNU control (0.25 % of CMC p.o. ), standard group (doxorubicin 2 mg/kg once in 4 days, i.p. ), C1 and C2 groups (50 mg/kg p.o. each). After 21 days of treatments, tumor volume
Gene Expression Tests for Women with Early Stage BreastCancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage BreastCancer: A Review of Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Gene Expression Tests for Women with Early Stage BreastCancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage BreastCancer: A Review of Clinical Utility and Cost (...) -Effectiveness Published on: October 16, 2017 Project Number: RC0934-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical utility of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence risk in women with early stage breastcancer? What is the comparative cost-effectiveness of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breastcancer patient with brain metastases 29067216 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breastcancer patient with brain metastases. e000253 10.1136/esmoopen-2017-000253 Central nervous system (CNS) involvement contributes to significant morbidity and mortality in patients with human epidermal growth factor receptor 2 (HER2 (...) )-positive metastaticbreastcancer (mBC) and represents a major challenge for clinicians. Liquid biopsy of cerebrospinal fluid (CSF)-derived circulating tumour DNA (ctDNA) harbours clinically relevant genomic alterations in patients with CNS metastases and could be effective in tracking tumour evolution. In a HER2-positive mBC patient with brain metastases, we applied droplet digital PCR (ddPCR) and next-generation whole exome sequencing (WES) analysis to measure ctDNA dynamic changes in CSF and plasma
Clinicopathological features and survival of early stage breastcancer in northwest China: A populationâ€based retrospective study of 1287 patients 28976077 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Clinicopathological features and survival of early stage breastcancer in northwest China: A population-based retrospective study of 1287 patients. 10-18 10.1111/1759-7714.12503 Breastcancer (BC) displays different clinicopathological features and outcomes based (...) Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Yi Min M Department of Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Yang Jin J Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. eng Journal Article 2017 10 04 Singapore Thorac Cancer 101531441 1759-7706 IM Int J Cancer. 2015 Mar 1;136(5):E359-86 25220842 Cancer. 2001 Apr 15;91(8 Suppl):1679-87 11309768 Breast
Breastcancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue 28979927 2018 11 13 2374-4677 3 2017 NPJ breastcancer NPJ BreastCancerBreastcancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue. 39 10.1038/s41523-017-0041-7 Studies have suggested that hormone receptor and Ki67 (...) expression in normal breast tissue are associated with subsequent breastcancer risk. We examined the associations of breastcancer risk factors with estrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor-1 receptor (IGF-1R), and Ki67 expression in normal breast tissue. This analysis included 388 women with benign breast disease (ages 17-67 years) in the Nurses' Health Studies. Immunohistochemical staining was performed on tissue microarrays constructed from benign biopsies
Digital Breast Tomosynthesis with Hologic 3D mammograhy Selenia Dimensions System for use in breastcancer screening Digital Breast Tomosynthesis with Hologic 3D mammography Selenia Dimensions System for use in breastcancer screening - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Digital Breast Tomosynthesis with Hologic 3D mammography Selenia Dimensions System for use in breastcancer screening Søk i Folkehelsa.no Search for: Søk (...) Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close Skip to content Background In Norway, breastcancer screening is offered through a publicly funded program to women in the age group 50-69 on a biennial basis. Breastcancer incidence is relatively higher among women in this age group than it is among younger women. The purpose of the screening program is to reduce breastcancer
Gene Expression Profiling in BreastCancer and Its Effect on Therapy Selection in Early-Stage BreastCancer 29082373 2018 11 13 13 4 2017 Oct European journal of breast health Eur J Breast Health Gene Expression Profiling in BreastCancer and Its Effect on Therapy Selection in Early-Stage BreastCancer. 168-174 10.5152/ejbh.2017.3636 Breastcancer is a heterogeneous disease. The purpose of adjuvant therapy for early-stage breastcancer is to provide maximum benefit with minimum side effects (...) in recent years, is beneficial in therapy selection for luminal breastcancer cases. A differentiation can be made among patients for whom only endocrine treatment would be adequate and those who should also receive chemotherapy in addition to endocrine treatment. Several new gene expression analysis studies targeted at gaining the ability to determine drug selection in chemotherapy, endocrine treatment and neo-adjuvant therapy are also currently ongoing. The staging system for new breastcancer
Roles of Biopsychosocial Factors in the Development of BreastCancer 29082379 2018 11 13 13 4 2017 Oct European journal of breast health Eur J Breast Health Roles of Biopsychosocial Factors in the Development of BreastCancer. 206-212 10.5152/ejbh.2017.3519 The aim of this study was to determine the roles of biopsychosocial risk factors in the development of breastcancer. This hospital-based case-control study included 491 women with breastcancer (study group) and 512 women who did not have (...) cancer or other serious diseases (control group). Biological, psychological, and social risk factors were compared between the two groups. Data were collected using the semi-structured interview, the Stress Assessment Form, and the Coping Strategy Indicator to assess these factors. When the significantly different biopsychosocial variables between the study and the control groups were evaluated together, independent breastcancer risk factors were found as follows: a stressor experienced in the last